The Pharma Letter

Enhertu plus pertuzumab Type II Variation application validated by EMA

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for Enhertu ...
Pharmabiz

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
Pharmabiz

EMA validates Type II Variation marketing authorization application of Datroway as first-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for Datroway (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...